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Abstract The decameric peptide SALQNAASIA from the
Mycobacterium bovis heat shock protein (hsp) 60 is recognized
by the murine T-cell receptor UZ-3-4 in complex with the mu-
rine class I major histocompatibility complex molecule H-2Db.
This T-cell receptor cross-reacts with the H-2Db-bound non-
homologous decameric peptide KDIGNIISDA from the murine
hsp60, but does not recognize the nonameric mycobacterial pep-
tide SALQNAASI. Cross-recognition of the KDIGNIISDA/H-
2Db complex induces autoimmune pathology in immunode¢cient
mice. We solved the X-ray crystal structure of the SALQNAA-
SIA/H-2Db complex at 3.0 A6 resolution, and we modelled the
KDIGNIISDA and SALQNAASI peptides in the H-2Db bind-
ing site. The structural analysis of the H-2Db-bound hsp60 epi-
topes o¡ers insight into T-cell receptor cross-reactivity.
8 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Heat shock proteins (hsps) are phylogenetically highly con-
served. Within the hsp60 family, the sequence identity be-
tween proteins from organisms as diverse as mammals and
mycobacteria is approximately 50%, and the similarity is
70%. Mycobacterium tuberculosis is the causative agent of tu-
berculosis (TB), while an attenuated strain of Mycobacterium
bovis, Bacille Calmette-Gue¤rin (BCG), is used as a vaccine
against TB. Recently, naked DNA encoding the hsp60 from
Mycobacterium leprae (95% identical to the M. tuberculosis
hsp60) was tested as a subunit vaccine in mice [1], the animal
model of choice for TB. The naked DNA vaccine provided
protection comparable to BCG, and was also successfully
used as a therapeutic agent for the treatment of infected mice
[2]. In both cases, the positive e¡ects were accompanied by
activation of antigen-speci¢c, CD8þ T-cell-mediated cellular
immunity. Cellular cytotoxicity has been recognized as an
important aspect of the immune response against TB [3,4].
The high similarity among hsp60s suggests the possibility of
immunological cross-reactivity between hsp60s of self and
pathogenic origins, with important implications for vaccine
safety. In vitro studies showed that major histocompatibility
complex (MHC) class I-restricted CD8þ T-cells raised against
mycobacterial hsp60 cross-react with stressed murine host
cells [5]. The M. bovis epitope, which is recognized by the
cross-reactive T-cell clone UZ-3-4 when bound to the class I
MHC molecule H-2Db, was identi¢ed as the decameric pep-
tide SALQNAASIA (hsp60499508) [6]. This peptide does not
conform to the optimal H-2Db binding motif [7], which has
Asn in P5 and a bulky hydrophobic residue in P6 (C-terminal
amino acid). The optimal peptide for binding to H-2Db, the
nonameric peptide SALQNAASI (hsp499507), does bind to
H-2Db, but is not recognized by the T-cell receptor (TCR)
UZ-3-4 [6]. The murine epitope recognized by UZ-3-4 also
came from the hsp60; however, the cross-reacting antigen
did not correspond to the homologous murine sequence, but
rather to the peptide KDIGNIISD(A) (hsp60162170=171) [8],
which shows low identity with the mycobacterial epitope.
Both immunization with mycobacterial hsp60 [4,8] and vac-
cination with BCG [4] stimulated CD8þ T-cell clones speci¢c
for the mycobacterial peptide hsp60499508, and these T-cells
cross-reacted with the murine hsp60162170=171. The use of my-
cobacterial hsp60 for vaccine design thus carries the danger of
an autoimmune response; adoptive transfer of the UZ-3-4
T-cell clone in immunode¢cient mice indeed induced autoim-
mune pathology [9].
We have previously analyzed the TCR expressed by the
T-cell clone UZ-3-4, and its interaction with the mycobacterial
peptide hsp60499508 SALQNAASIA (termed ASIA for short)
in complex with H-2Db [10]. In the present study, we extend
our biophysical characterization of the molecules involved in
the protective immune response and the autoimmune reaction
described above. We have solved the crystal structure, deter-
mined at 3.0 AH resolution, of the ASIA/H-2Db complex, and
we have modelled both the mycobacterial peptide hsp60499507
SALQNAASI (termed ASI for short), and the murine peptide
hsp60162171 KDIGNIISDA (termed ISDA for short), in the
H-2Db binding site. A comparison of the three peptide/H-2Db
complexes o¡ers an insight into the cross-reactivity of the
TCR UZ-3-4.
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2. Materials and methods
2.1. Protein expression and puri¢cation
The SALQNAASIA/H-2Db complex was prepared as previously
reported [10].
2.2. Crystallization
Crystals were grown by the hanging drop vapor di¡usion method,
by mixing 2 Wl of protein solution with 2 Wl of reservoir solution at
4‡C. The protein solution (10 mg/ml) contained 150 mM NaCl and
20 mM Tris, pH 8.0. The reservoir solution contained 2.0 M ammo-
nium sulfate, 15% v/v glycerol, and 0.1 M Tris, pH 8.0.
2.3. Data collection and processing
A full dataset was collected to a maximum resolution of 3.0 AH ,
from a crystal £ash-frozen in a stream of liquid N2 at 100 K. The
data were collected at the Swiss^Norwegian Beam Line, Station
BM1A, at the ESRF, Grenoble, France.
The data were processed and scaled with the HKL package [11]
(Denzo and Scalepack). The crystal belongs to the space group C2.
Data statistics are presented in Table 1.
2.4. Structure solution and re¢nement
The structure was solved by molecular replacement with AMoRe
[12], using the Flu/H-2Db complex [13] (PDB code: 1HOC) as a
search model, after removal of the peptide. Four H-2Db molecules
were found in the asymmetric unit.
Cycles of structure re¢nement in CNS [14] were alternated with
manual rebuilding of the model in O [15]. The peptide was initially
added as a poly-alanine model, and the appropriate side chains were
introduced at later stages. Strong non-crystallographic symmetry re-
straints (300 kcal/mol/AH 2) were applied at the beginning of the re¢ne-
ment, and were partially released (100 kcal/mol/AH 2) at the end.
Grouped B factor re¢nement was performed, re¢ning two B values
per residue (main chain and side chain atoms). The ¢nal Rwork and
Rfree were 24.6% and 30.7%. A summary of the crystallographic sta-
tistics is shown in Table 1. The atomic coordinates and structure
factors have been deposited in the Protein Data Bank (PDB code:
1N3N)
2.5. Molecular modeling
The molecular models of the ISDA/H-2Db and ASI/H-2Db com-
plexes are based on the crystal structure of ASIA/H-2b (this study)
and Flu/H-2Db [13], respectively. The peptide side chains were man-
ually mutated in O; rotamer selection was based on potential hydro-
gen bonds and steric complementarity with the H-2Db binding site.
Afterwards, 200 steps of conjugate gradient minimization were per-
formed in CNS.
3. Results
3.1. Crystal structure of the ASIA/H-2Db complex
In the ¢nal model, four peptide/H-2Db complexes are
present in the asymmetric unit (MolA, MolB, MolC, and
MolD). MolA and MolB have the same orientation in the
Table 1
Crystallographic statistics
Space group C2
Cell parameters
a (AH ) 129.28
b (AH ) 123.00
c (AH ) 150.83
K (‡) 90
L (‡) 90.01
Q (‡) 90
Molecules per asymmetric unit 4
Data collection
Resolution limit (AH ) 3.00
Outermost shell (AH ) 3.11^3.00
Unique re£ectionsa 47 412 (4725)
Redundancya 3.8 (3.8)
Completenessa (%) 99.9 (100.0)
Average I/ca 13.6 (4.5)
Rmerge a;b (%) 9.3 (40.0)
Re¢nement
Rwork c (%) 24.6
Rfree d (%) 30.7
Number of water molecules 189
Rmsd bonds (AH ) 0.013
Rmsd angles (‡) 1.54
Average B values (AH 2)
All protein atoms 53.6
MHC 54.0e
Peptide 36.9e
Waters 26.1
Ramachandran plot regionsf
Most favored regions (%) 81.1
Additional allowed regions (%) 17.7
Generously allowed regions (%) 1.2
Disallowed regions (%) 0.0
aNumbers in parentheses refer to the outermost resolution shell.
bRmerge ¼
P
hkl
P
jMI j;hkl3GIhklfM=
P
hkl
P
j I j;hkl , where GIhklf is the aver-
age of the intensity Ij;hkl over j=1, T, N observations of symmetry-
equivalent re£ections hkl.
cRwork ¼ ð
P
hklMMFoM3MF cMMÞ=
P
hklMFoM, where MFoM and MFcM are
the observed and calculated structure factor amplitudes, respectively.
dRfree is the same as Rwork but is calculated using 3% of the re£ec-
tions that were excluded from the re¢nement.
eThis value refers to all four molecules in the asymmetric unit.
fCalculated with PROCHECK [37].
Fig. 2. Top view of the H-2Db binding site, showing the CK trace
of the ASIA peptide (red) superimposed on the in£uenza virus (pur-
ple) and Sendai virus (cyan) peptides. The superposition is based on
the CK atoms of the K1- and K2-helices, which are also shown. Pic-
ture made with SETOR [35].
Fig. 1. Electron density map of the H-2Db-bound ASIA peptide.
The peptide is oriented above the £oor of the binding site, and is
viewed from the K2-helix side of the MHC heavy chain. The K1-he-
lix is behind the peptide. The Fo3Fc simulated annealing (2000 K)
omit map is contoured at the 2.5 c level. Picture made in SETOR
[35].
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asymmetric unit, and are related by simple translation; the
same relationship applies to MolC and MolD. The average
root mean square deviation for the CK of the bound peptides
is 0.17 AH ; our analysis will be restricted to the peptide bound
to MolA.
Peptide binding to a given class I MHC molecule requires
the presence of ‘anchor residues’, which complement the phys-
icochemical characteristics of the speci¢city pockets [16] of the
MHC molecule’s binding site. In the case of the murine
H-2Db, the peptide binding motif [7] includes Asn in P5 and
an Ile/Leu/Met at the C-terminal position (P6), which gener-
ally corresponds to position 9. However, exceptions are
known regarding both anchor residues [17] and peptide length
[18]. The decameric peptide ASIA, shown in Fig. 1, presents a
double exception, being longer and possessing a non-standard
P6 anchor residue (AlaP10). For comparison, Fig. 2 shows a
superposition in the MHC binding groove of ASIA and two
nonameric peptides of known crystal structure. The two pep-
tides are from Sendai virus (FAPGNYPAL) [19], and from
in£uenza virus (Flu, ASNENMETM) [13]. In our crystal
structure, the side chain of AlaP10 leaves an 80 AH 3 void in
the F pocket (volume calculated with Voidoo [20], using a
1.4 AH radius rolling probe). In other crystal structures of pep-
tide/H-2Db complexes [13,17,18,21] the large, hydrophobic F
pocket is ¢lled up by P6 residues that have bulky, hydro-
phobic side chains. Nevertheless, the position of the AlaP10
CK is unchanged (Fig. 2), and the C-terminal carboxylate
forms a set of conserved hydrogen bonds with H-2Db side
chains (Fig. 3). H-2Db-bound peptides form a pronounced
bulge in their C-terminal portion [13,17,18,21], between the
anchor positions P5 and P6, due to the presence of a hydro-
phobic ridge (formed by Trp73, Trp147, and Tyr156) that lies
across the binding site; such a bulge is more pronounced in
longer peptides [18], where more residues are interposed be-
tween the anchors. The decameric ASIA peptide rises above
the £oor of the binding site and kinks (Fig. 2) between AlaP6
and SerP8. Consequently, AlaP7 is completely solvent-exposed,
and contributes 111 AH 2 to the total of 264 AH 2 solvent-acces-
sible surface (SAS) of the peptide (areas calculated with Area-
imol [22], using a 1.7 AH radius probe). The only other residue
that contributes signi¢cantly to the SAS is GlnP4 (86 AH 2). The
carbonyl oxygen of AlaP6 is hydrogen-bonded to Trp73 NO1,
and the SerP8 carbonyl oxygen is hydrogen-bonded, via a
water molecule, to Tyr156 of the heavy chain (Fig. 3): this
pair of hydrogen bonds was shown to drive the position of the
Fig. 4. Top view of the H-2Db binding site, showing the CK trace
of the ASIA peptide (red) superimposed on the modeled ISDA
(green) and ASI (blue) peptides. The superposition is based on the
CK atoms of the K1- and K2-helices, which are also shown. Picture
made with SETOR [35].
Fig. 3. Crucial interactions between the C-terminal half of the ASIA
peptide and the H-2Db binding groove. The backbones of the
K1- and K2-helices are shown as orange ribbons. Hydrogen bonds
between peptide and MHC are shown as yellow dots. Two water
molecules (purple), mediating further hydrogen bonds (purple), are
shown in an Fo3Fc omit map, contoured at the 3.5 c level. Picture
made in SETOR [35].
Fig. 5. Surface representation of the hsp60-derived peptide/H-2Db
complexes, showing the variation in solvent accessibility of the anti-
genic peptides. The binding sites are viewed from the top; the
MHC atoms are mapped onto the surface in white, and the peptides
in yellow. The C-terminal ends of the peptides are on the right.
a: The modeled ISDA peptide; b: the ASIA peptide; c: the mod-
eled ASI peptide. Picture made with GRASP [36].
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P6 CK towards the K2-helix [18,21]. Another crucial interac-
tion for determining the peculiar conformation of ASIA is
between SerP8 and Ser150, which is located on the K2-helix;
the two residues form a hydrogen bond (Fig. 3), and an or-
dered water molecule cross-links their side chains. The net
result of this hydrogen bond network is an overall shift of
the peptide backbone towards the K2-helix of the MHC mol-
ecule, when compared to other H-2Db-bound peptides (Fig. 2
and Fig. 2a in [18]). This shift occurs between P5 and P10;
only the extra residue, AlaP7, is positioned towards the center
of the binding groove.
3.2. Modeling of ASI and ISDA in the H-2Db binding site
The nonameric mycobacterial peptide ASI and the decame-
ric murine peptide ISDA were modeled in the H-2Db binding
site based on the nonameric Flu structure [13] and the deca-
meric ASIA structure, respectively. The choice of the Flu
complex [13] is justi¢ed by its bound peptide having an ‘in-
termediate’ conformation among H-2Db-bound nonameric
peptides [18], with the backbone positioned close to the center
of the binding cleft. The ASIA complex was chosen since it is
the only known H-2Db structure that contains a decameric
peptide. Fig. 4 shows that assigning the role of C-terminal
anchor residue to IleP9 of ASI forces the peptide backbone
in an extended conformation, as seen in other nonameric pep-
tides (Fig. 2). This drastically decreases the peptide’s SAS to
204 AH 2, with a dominant contribution from GlnP4 (72 AH 2) and
AlaP6 (54 AH 2). Conversely, the decameric peptide ISDA,
which binds to H-2Db using AlaP10 as C-terminal anchor res-
idue, is predicted to retain a conformation which is compara-
ble to ASIA (Fig. 4). Despite its bulkier side chain, IleP6 can
be accommodated on a hydrophobic shelf that forms the D
pocket [16], with a small deviation of the CK position towards
the center of the binding site (Fig. 4). The position of SerP8 is
conserved, as well as its interaction with the K2-helix. The
backbone kink at position P7 is preserved, and IleP7 contrib-
utes 191 AH 2 to the peptide’s SAS (313 AH 2) ; the P4 residue
(Gly) now has a very small SAS (23 AH 2).
4. Discussion
In the ASIA/H-2Db crystal structure, the anchor residue
AlaP10 only partially ¢lls the F pocket, leaving an 80 AH 3 cavity
in the binding groove. The presence of cavities at the peptide/
MHC interface has been associated with decreased thermal
stability of the peptide/MHC complex (pMHC) [23]. The sub-
stitution of a pocket-¢lling P6 anchor residue, such as Leu
[18,19], with Ala should be accompanied by a free energy cost
[24]. This can be approximated as a constant term (V2 kcal/
mol), which is equivalent to the transfer free energy from
water to organic solvent of Leu relative to Ala, and a variable
term (24^33 cal/mol/AH 3), which is proportional to the cavity
volume [24]. In the present case, the estimated free energy cost
of using Ala instead of Leu as the P6 anchor is between 3.9
and 4.6 kcal/mol. In contrast, a similar substitution in the
in£uenza virus matrix peptide bound to the human HLA-A2
did not change the thermal stability of the complex [25]. The
energetic cost of this substitution is therefore undetermined
for H-2Db, and must be measured experimentally. Thus the
question remains open whether the preference shown by
F pockets for bulky hydrophobic residues, such as Leu rather
than Ala, is intrinsic to H-2Db (and HLA-A2 as well), or
stems merely from the speci¢city of the proteasome [26],
which generates the C-terminus of antigenic peptides.
The murine T-cell clone UZ-3-4, obtained from mice immu-
nized with mycobacterial hsp60, was shown to be speci¢c for
the H-2Db-bound M. bovis hsp60 epitope ASIA [6], and to
cross-react with the murine hsp60 epitope ISDA [8]. In con-
trast, the M. bovis hsp60 peptide ASI is not recognized [6].
The crystal structure presented here shows that the decameric
peptide ASIA bound to H-2Db assumes a peculiar conforma-
tion (Fig. 2 and [18]), which is distinct from other H-2Db-
bound peptides. The shift of the C-terminal part of the pep-
tide from the center of the binding groove towards the K2-
helix and the kink observed in P7 are determined by the
length of the peptide (10 residues), the use of Ala as the P6
anchor residue, and the presence of Ser in position P632
(Fig. 3). These features are present in ISDA, but not in
ASI. Despite the low sequence identity (3/10) and similarity
(6/10), the ISDA/H-2Db model shows that ISDA can retain
the same backbone conformation as ASIA (Fig. 4). TCR rec-
ognition is generally thought to use £exible binding surfaces
[27], and a two-step mechanism where peptide contact follows
docking onto the MHC [28]. Both features favor cross-reac-
tivity towards MHC-bound peptides that retain a su⁄cient
level of structural similarity. The increased SAS of ISDA
(Fig. 5a) in comparison with ASIA (Fig. 5b) is mostly due
to the Ala to Ile mutation in P7. The KD describing the UZ-3-
4/ASIA/H-2Db interaction is V100 WM [10], which puts it in
the low a⁄nity range for TCR recognition, and hints at a
poor surface complementarity at the TCR/pMHC interface
[29]. The bulky IleP7 in ISDA (Fig. 5a) could promote better
interaction with UZ-3-4. A similar e¡ect was observed for the
A6 TCR interacting with alkyl substitutes of a Tax peptide
mutant bound to HLA-A2 [29], where better packing at the
TCR/pMHC interface lead to higher a⁄nity. Importantly, a
KD lower than 100 WM, re£ecting higher a⁄nity for the mu-
rine self-peptide ISDA bound to H-2Db, would not exceed the
a⁄nity threshold (KDW10 WM [30]) for positive thymocyte
selection, and would thus allow the conservation of UZ-3-4
in the murine TCR repertoire.
Modeling shows that ASI in complex with H-2Db cannot
assume the peculiar backbone conformation shared by ASIA
and ISDA (Fig. 4). Furthermore, crystal structures of TCR/
pMHC complexes show that antigenic peptides contribute, on
average, 250 AH 2 to the TCR/pMHC interface [31], and only in
one case less than 200 AH 2. The total SAS of ASI (Fig. 5c) in
complex with H-2Db is an inconspicuous 204 AH 2, and only
100 AH 2 for its C-terminal portion; these simple facts can ex-
plain the lack of recognition by UZ-3-4.
The high immunogenicity of microbial heat shock proteins
(reviewed in [32]) makes them attractive candidates for sub-
unit vaccine development, and hsp60 has been used with suc-
cess for a naked DNA vaccine against TB [1,2] in mice. At the
same time, the high similarity between hsp60 in mycobacteria
and mammals raises concerns about the possibility of cross-
reaction and an induced autoimmune response [32]. Indeed,
TCR cross-recognition of the mycobacterial and murine hsp60
was observed [8], as well as hsp60-linked autoimmune pathol-
ogy [9]. However, the present study suggests that the observed
cross-recognition of self and non-self hsp60 epitopes by the
TCR UZ-3-4 strictly depends on the restricting class I MHC
molecule, H-2Db. It is noteworthy that most of the DNA
vaccine experiments [1,2] were performed in BALB/c mice
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(H-2d haplotype), which do not express H-2Db. BALB/c mice
express H-2Ld, which is similar in sequence [33] to H-2Db,
and in structure [34], since also its binding groove possesses
the hydrophobic ridge composed of Trp73, Trp147, and
Tyr156. Nevertheless, H-2Ld prefers Pro as the P2 anchor
residue, and will not bind ASIA or ISDA. Therefore, the
absence of adverse e¡ects in inbred BALB/c may be attributed
to their speci¢c genetic make-up.
In conclusion, our analysis shows that cross-reactivity be-
tween homologous self and non-self antigens can be due to
subtle structural factors which cannot be revealed by sequence
similarity, and that the genetic background of the animal
models is of importance. Incorporation of this kind of struc-
tural information can also help in the rational analysis of new
vaccines.
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